In the MonarchE trial, recruitment was permitted up to 16 months after surgery; therefore, sequential treatment involving 1 year of olaparib followed by 2 years of abemaciclib could be considered for the selected patients with high-risk HR+/HER2- early-stage breast cancer and germline BRCA1/2 mutation. The gene discussed is BRCA1; the disease is breast cancer.